Praxis Precision Medicines To Provide Corporate Update And Report Third Quarter 2021 Financial Results On Wednesday, November 3, 2021
Praxis Precision Medicines (NASDAQ: PRAX) will provide a corporate update and report its Q3 2021 financial results on November 3, 2021, before U.S. market opens. The management team will discuss recent business progression and pipeline developments during a conference call at 8:30 a.m. ET. Praxis specializes in creating therapies for CNS disorders, utilizing genetic insights to enhance treatment strategies. The company has a diverse portfolio targeting epilepsy, depression, movement disorders, and pain syndromes, with three clinical-stage candidates.
- Upcoming conference call on Nov 3, 2021, to discuss business and pipeline progress.
- Focus on developing therapies for CNS disorders utilizing genetic insights.
- Broad portfolio addressing multiple CNS disorders including epilepsy and depression.
- None.
BOSTON, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that it will provide a corporate update and report financial results for the third quarter 2021 on Wednesday, November 3, 2021, before the U.S. financial markets open. Management will discuss recent business and pipeline progress via a conference call and webcast at 8:30 a.m. ET.
| Conference Call and Webcast Details: | |
| US/Canada Toll Free: | 833-398-1037 |
| International: | 914-987-7735 |
| Conference ID: | 7687942 |
| Webcast: | https://edge.media-server.com/mmc/p/8yk7hqak |
A replay of the webcast will be available approximately two hours following its conclusion and will be archived for 30 days following the event, accessible through the Events & Presentations page of the Investors + Media section of Praxis’ website at https://investors.praxismedicines.com/events-and-presentations.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying insights from genetic epilepsies to broader neurological and psychiatric disorders, using our understanding of shared biological targets and circuits in the brain. Praxis has established a broad portfolio, including multiple disclosed programs across CNS disorders including depression, epilepsy, movement disorders and pain syndromes, with three clinical-stage product candidates. For more information, please visit https://praxismedicines.com/ and follow us on LinkedIn and Twitter.
FAQ
When will Praxis Precision Medicines report its Q3 2021 financial results?
What time is the conference call for Praxis Precision Medicines?
What is the ticker symbol for Praxis Precision Medicines?
What types of disorders does Praxis Precision Medicines focus on?
